HK Stock Market Move | TYK MEDICINES-B (02410) surged over 40%. The key registration phase II clinical results of Eliotinib were recently featured in the WCLC oral presentation.

TYK MEDICINES-B(02410) surged more than 40% in the morning session, closing with a 37.9% increase at HK$21.36, with a transaction volume of HK$1.664 billion. On the news front, the innovative drug Alectinib tablet (TY-9591) independently developed by Tongyuan Kang Pharmaceutical for the key Phase II clinical trial (NCT05948813) targeting EGFR mutated advanced non-small cell lung cancer (NSCLC) recently received a Mini Oral presentation at the WCLC 2025 conference. It is reported that the ESAONA key registration trial selected for Mini Oral presentation is an open, multicenter, randomized controlled Phase II clinical trial focused on NSCLC patients with EGFR mutation (L858R or 19Del) with brain metastases, aiming to compare the first-line efficacy and safety of Alectinib (160mg, once daily) versus Osimertinib (80mg, once daily) in untreated NSCLC patients with EGFR-sensitive mutations and brain metastases. As of February 28, 2025, a total of 257 EGFR mutated NSCLC patients with brain metastases were enrolled in the study. In terms of efficacy, the mid-term analysis based on data from 224 patients showed that, according to RECIST criteria evaluation, the blinded independent central review (BICR) objective intracranial response rate (iORR) was as high as 92.8% (95% CI: 86.3-96.8%) in the Alectinib group, while it was 76.1% (95% CI: 67.2-83.6%) in the Osimertinib group, with a P value of 0.0006. The selection of Alectinib to challenge Osimertinib in the key Phase II clinical trial results for a Mini Oral presentation at this WCLC conference signifies the international academic recognition of its efficacy and safety data, demonstrating significant clinical transformation potential.